PMC-122 / PharmAbcine - LARVOL DELTA

Effectiveness of Upadacitinib in Refractory Skin and Rapidly Progressive Lung Manifestations of Myositis (CRA-AHPA 2026) - "Background: Limited data is available on the use of Upadacitinib in idiopathic inflammatory myositis, as most available studies have focused on tofacitinib as a therapeutic option to target the interferon pathway...He then developed a spontaneous pneumothorax and ILD flare and was admitted for addition of rituximab (1g on day 0 and day14) along with IVIG...She had previously received multiple therapies: methotrexate, azathioprine, mycophenolate mofetil, hydroxychloroquine, IVIG (discontinued due to migraines), and abatacept with persistent disease activity and difficulty tapering prednisone... Addition of Upadacitinib may represent a promising therapeutic option for idiopathic inflammatory myositis, demonstrating efficacy in the different disease domains of lung and skin in patients refractory to standard therapy, potentially by targeting the interferon pathway. References: -Beckett, M., Dutz, J., & Huang, K. et al. (2024)."

CNS Disorders • Dermatomyositis • Fibrosis • Immunology • Interstitial Lung Disease • Migraine • Myositis • Pulmonary Disease • Respiratory Diseases • IFIH1

Simultaneously Integrated Protection in SBRT of Pancreas - An International Planning Benchmark Study (ESTRO 2023) - "PMID: 27757502; PMCID: PMC5122615...Epub 2022 Jan 22. PMID: 35074434."

Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor